Johnson & Johnson JNJ

NYS: JNJ | ISIN: US4781601046   10/06/2026
238,49 USD (+0,63%)
(+0,63%)   10/06/2026
Grafiek Johnson & Johnson Grafiek Johnson & Johnson

Johnson & Johnson in het nieuws

8 juni 2026 · Johnson & Johnson neemt Firefly Bio over voor 1 miljard dollar en zet in op doorbraak in KRAS-kankerbehandeling · Business AM

Key takeaways Johnson & Johnson heeft een overeenkomst aangekondigd ter waarde van 1 miljard dollar (866,2 miljoen euro), volledig in contanten, voor de overname van Firefly Bio, een biotechnologiebedrijf dat gespecialiseerd...

3 juni 2026 · Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study · Persbericht

3 juni 2026 · Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease · Persbericht

31 mei 2026 · RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited · Persbericht

31 mei 2026 · Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm · Persbericht

29 mei 2026 · RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer · Persbericht

29 mei 2026 · New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma · Persbericht

29 mei 2026 · FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage · Persbericht

14 mei 2026 · Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation · Persbericht

11 mei 2026 · Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP · Persbericht

Profiel Johnson & Johnson

Fabricage van farmaceutische preparaten
Farmaceutica
Gezondheidstechnologie
Productie

Website: www.jnj.com

Hoofdzetel: New Brunswick, New Jersey vlag Verenigde Staten

Mijn selecties